Pharmafile Logo
Pharmafocus logo
Advanced Search

CGPR

Showing 1 posts of 1 posts found.

neurons-3743011_960_720

Biohaven’s CGPR antagonist migraine treatment beats placebo in Phase 3 trial

July 11, 2019
Research and Development Biohaven, CGPR, clinical trials, headache, migraine, pharma

Connecticut-based firm Biohaven has said its migraine drug rimegepant showed superiority over placebo in a Phase 3 clinical trial. The …

News
The Gateway to Local Adoption Series

Latest content

AbbVie expands Oxford R&D facility with new £120m UK research commitment

November 9, 2026

MedPharm appoints Jason Mieding as chief operating officer

November 8, 2026

UKRI backs five hubs developing AI tools for earlier disease detection

November 8, 2026

Coriolis Pharma appoints Teun van der Heide as CEO

November 7, 2026

NEC joins €6.5m European project using AI for pandemic vaccine design

November 6, 2026